DEVELOPING
Importance
55
Trust
71
Urgency
65
COMMERCIAL
‘No change’ for CagriSema as Novo ditches single-chamber device - Fierce Biotech
Novo Nordisk is dropping a single-chamber injection device for CagriSema, a two-drug weight-loss shot combining cagrilintide and semaglutide. The company says the change won't affect when CagriSema reaches patients.
Analysis
Novo dropped a one-shot device for its new weight-loss drug CagriSema. The company says patients will still get the drug on time.
- Novo Nordisk dropped the single-chamber injection device for CagriSema
- CagriSema combines cagrilintide and semaglutide for weight loss
- Novo says the device change will not delay CagriSema's launch timeline
FierceBiotech1mo
Read